Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: A pilot open-label study

Movement Disorders

Volumn 24, Issue 2, 2009, Pages 277-282

  Marsh, Laura ^a   Biglan, Kevin ^a,b   Gerstenhaber, Melissa ^a   Williams, James R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Atomoxetine; Cognition; Executive dysfunction; Norepinephrine reuptake inhibition; Parkinson's disease

Indexed keywords

AMANTADINE; ANTIDEPRESSANT AGENT; APOMORPHINE; ATOMOXETINE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; HYPNOTIC AGENT; LEVODOPA; SELEGILINE;

ADULT; AGED; AGITATION; ARTICLE; ATTENTION DISTURBANCE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; CONNORS ADULT ADHD RATING SCALE; CONSTIPATION; DEPRESSION; DIAPHORESIS; DREAMING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; DYSMENORRHEA; FATIGUE; FEMALE; FRONTAL SYSTEMS BEHAVIOR SCALE EXECUTIVE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERKINESIA; HYPOMANIA; MALE; MEMORY; MOTOR DYSFUNCTION; MUSCLE RIGIDITY; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PARESTHESIA; PARKINSON DISEASE; PILOT STUDY; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; TREATMENT DURATION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ADULT; AGED; ANTIPARKINSON AGENTS; BIPOLAR DISORDER; COGNITION DISORDERS; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL DISEASES; HUMANS; MALE; MIDDLE AGED; NOOTROPIC AGENTS; PARKINSON DISEASE; PILOT PROJECTS; PREFRONTAL CORTEX; PROPYLAMINES; PSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 61649118193     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22307     Document Type: Article

References (37)

1. Dubois B, Pillon B. Cognitive deficits in Parkinson's disease. J Neurol 1997;244:2-8.
2. Campbell JJ, Duffy JD, Salloway SP. Treatment strategies for patients with dysexecutive syndromes. In: Salloway SP, Malloy PF, Duffy JD, editors. The frontal lobes and neuropsychiatric illness. Washington, DC: American Psychiatric Publishing. 2002. p 153-163.
3. Woods SP, Tröster AI. Prodromal frontal/executive dysfunction predicts incident dementia in Parkinson's disease. J Int Neuropsychol Soc 2003;9:17-24.
4. Caviness JN, Driver-Dunckley E, Connor DJ, et al. Defining mild cognitive impairment in Parkinson's disease. Mov Disord 2007;22:1272-1277.
5. Cools R, Swainson R, Owen AM, Robbins TW. Cognitive dysfunction in non-demented Parkinson's disease. In: Wolters EC, Sheltens Ph, Berendse HW, editors. Mental dysfunction in Parkinson's disease II. Utrecht: Academic Pharmaceutical Productions; 1999. p 142-164.
6. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
7. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
8. Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology 1993;43:2412-2414.
9. Reisberg B. Functional assessment staging (FAST). Psychopharm Bull 1988;24:653-659.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's disease cooperative study-clinical global impression of change. Alzheimer Dis Assoc Disord 1997;11 (Suppl 2):S22-S32.
12. Grace J, Malloy P. Frontal systems behavior scale (FrSBe). Lutz, FL: Psychological Assessment Resources; 2001.
13. Conners CK, Erhardt D, Sparrow EP. Conners' adult ADHD rating scales (CAARS). Technical manual. North Tonawanda, NY: Multi-Health Systems; 1999.
14. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry 2003;53:112-120.
15. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K. The Udvalg for Kliniske Undersogelser (UKU) side effect rating scale: a new comprehensive rating scale for psychotropic drugs, and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 1987;Suppl 76:1-100.
16. Fahn S, Elton RL, Members of the UPDRS development committee. Unified Parkinson's disease rating scale. In: Fahn S, Marsden CD, Goldstein M, editors. Recent developments in Parkinson's disease II. New York: Macmillan; 1987:153-163.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
18. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf 2003; 26:729-740.
19. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994;44: 2308-2314.
20. de Boer AG, Wijker W, Speelman JD, de Haes JC. Quality of life in patients with Parkinson's disease: development of a questionnaire. J Neurol Neurosurg Psychiatry 1996;61:70-74.
21. Sammer G, Reuter I, Hullmann K, Kaps M, Vaitl D. Training of executive functions in Parkinson's disease. J Neurol Sci 2006; 248:115-119.
22. Linazasoro G, Lasa A, Van Blercom N. Efficacy and safety of donepezil in the treatment of executive dysfunction in Parkinson disease: a pilot study. Clin Neuropharmacol 2005;28:176-178.
23. Williams-Gray CH, Foltynie T, Brayne CE, Robbins TW, Barker RA. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130(Part 7):1787-1798.
24. Sallee FR, Smirnov A. Atomoxetine: novel therapy for attention-deficit/ hyperactivity disorder and potential therapeutic implications. Primary Psychiatry 2003;10:41-48.
25. Tzavara ET, Bymaster FP, Overshiner CD, et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 2006;11:187-195.
26. Robinson ES, Eagle DM, Mar AC, et al. Similar effects of the selective noradrenaline reuptake inhibitor atomoxetine on three distinct forms of impulsivity in the rat. Neuropsychopharmacology 2008;33:1028-1037.
27. Chamberlain SR, Del Campo N, Dowson J, et al. Atomoxetine improved response inhibition in adults with attention deficit/hyperactivity disorder. Biol Psychiatry 2007;62:977-984.
28. Chamberlain SR, Müller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science 2006;311:861-863.
29. Spencer T, Biederman J, Wilens T, et al. Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disoder. Am J Psychiatry 1998;155:693-695.
30. Faraone SV, Biederman J, Spencer T, et al. Atomoxetine and stroop task performance in adult attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2005;15:664-670.
31. Riekkinen M, Kejonen K, Jäkälä P, Soininen H, Riekkinen P Jr. Reduction of noradrenaline impairs attention and dopamine depletion slows responses in Parkinson's disease. Eur J Neurosci 1998;10:1429-1439.
32. Bedard MA, el Massioui F, Malapani C, et al. Attentional deficits in Parkinson's disease: partial reversibility with naphtoxazine (SDZ NV1-085), a selective noradrenergic alpha 1 agonist. Clin Neuropharmacol 1998;21:108-117.
33. Stern Y, Mayeux R, Côté L. Reaction time and vigilance in Parkinson's disease. Arch Neurol 1984;41:1086-1089.
34. Camicioli R, Lea E, Nutt JG, Sexton G, Oken B. Methylphenidate increases the motor effects of l-dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol 2001;24:208-213.
35. Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:470-475.
36. Brusa L, Bassi A, Stefani A, et al. Pramipexole in comparison to l-dopa: a neuropsychological study. J Neural Transm 2003;110: 373-380.
37. Steinberg S, Chouinard G. A case of mania associated with tomoxetine. Am J Psychiatry 1985;142:1517-1518.